FDA suggests alternative approaches for nitrosamine risk assessments
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesNorth AmericaOTCPharmaceuticalsRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesNorth AmericaOTCPharmaceuticals